These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 17363490)

  • 21. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.
    Mimeault M; Jouy N; Depreux P; Hénichart JP
    Prostate; 2005 Feb; 62(2):187-99. PubMed ID: 15389789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
    Burich RA; Holland WS; Vinall RL; Tepper C; White RW; Mack PC
    BJU Int; 2008 Nov; 102(10):1458-66. PubMed ID: 18565171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.
    Lo Nigro C; Maffi M; Fischel JL; Formento P; Milano G; Merlano M
    BJU Int; 2008 Aug; 102(5):622-7. PubMed ID: 18494832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
    Bonaccorsi L; Marchiani S; Muratori M; Forti G; Baldi E
    J Cancer Res Clin Oncol; 2004 Oct; 130(10):604-14. PubMed ID: 15258753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
    Sakai I; Miyake H; Terakawa T; Fujisawa M
    Cancer Sci; 2011 Apr; 102(4):769-75. PubMed ID: 21214673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Wilding G; Soulie P; Trump D; Das-Gupta A; Small E
    Cancer; 2006 May; 106(9):1917-24. PubMed ID: 16568471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
    Guérin O; Formento P; Lo Nigro C; Hofman P; Fischel JL; Etienne-Grimaldi MC; Merlano M; Ferrero JM; Milano G
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):51-7. PubMed ID: 17593391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
    Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
    Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
    J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
    Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
    PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclopamine increases the radiosensitivity of human pancreatic cancer cells by regulating the DNA repair signal pathway through an epidermal growth factor receptor‑dependent pathway.
    Wu XY; Che J; Sun KK; Shen XJ; Yang D; Zhong N; Zhao H
    Mol Med Rep; 2013 Oct; 8(4):979-83. PubMed ID: 23903906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined targeting of EGFR and HER2 against prostate cancer stem cells.
    Rossini A; Giussani M; Ripamonti F; Aiello P; Regondi V; Balsari A; Triulzi T; Tagliabue E
    Cancer Biol Ther; 2020 May; 21(5):463-475. PubMed ID: 32089070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells.
    Sirab N; Terry S; Giton F; Caradec J; Chimingqi M; Moutereau S; Vacherot F; de la Taille A; Kouyoumdjian JC; Loric S
    Int J Cancer; 2012 Sep; 131(6):1297-306. PubMed ID: 22131072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.
    Borghese C; Cattaruzza L; Pivetta E; Normanno N; De Luca A; Mazzucato M; Celegato M; Colombatti A; Aldinucci D
    J Cell Biochem; 2013 May; 114(5):1135-44. PubMed ID: 23192362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
    Arisan ED; Obakan P; Coker-Gurkan A; Calcabrini A; Agostinelli E; Unsal NP
    Curr Pharm Des; 2014; 20(2):180-8. PubMed ID: 23701543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
    Monteverde M; Tonissi F; Fischel JL; Etienne-Grimaldi MC; Milano G; Merlano M; Lo Nigro C
    Urol Oncol; 2013 Aug; 31(6):776-86. PubMed ID: 21795074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signaling mechanisms that mediate invasion in prostate cancer cells.
    Bonaccorsi L; Marchiani S; Muratori M; Carloni V; Forti G; Baldi E
    Ann N Y Acad Sci; 2004 Dec; 1028():283-8. PubMed ID: 15650253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.